Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety and effectiveness of 131I-TM601 in the treatment of adult patients with progressive or recurrent malignant gliomas.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
TransMolecular
NCT05902169 · Glioblastoma, Recurrent Glioblastoma, and more
NCT05303467 · Glioblastoma Multiforme, Recurrent Glioblastoma
NCT07464925 · Glioblastoma Multiforme of Brain, Glioma, and more
NCT01269853 · Glioblastoma Multiforme, Anaplastic Astrocytoma
NCT05271240 · Glioblastoma, Glioblastoma Multiforme, and more
University of Chicago
Chicago, Illinois
Johns Hopkins University
Baltimore, Maryland
St. Mary's Health Care
Grand Rapids, Michigan
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions